Improvement of post-heparin lipolytic activity (PHLA) after haemofiltration, in uraemic patients. 1980

S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man

The decrease of serum PHLA in uraemic patients has been attributed to toxic effects of 'middle molecules' on lipoprotein lipase. Haemofiltration could improve PHLA by increasing 'middle molecule' clearance. Serum triglyceride concentration decreased and PHLA improved in three uraemic patients who received haemofiltration during three weeks as the initial treatment schedule. Activated PHLA of a healthy subject failed to be inhibited by uraemic sera and uraemic plasma ultrafiltrates obtained in vitro using polyacrylonitrile and cuprophane membranes. CONCLUSIONS haemofiltration is able to improve PHLA and to restore normal serum triglyceride concentrations. The reported toxicity of uraemic serum may affect metabolic steps preceding the activation of the circulating lipolytic enzymes.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008066 Lipolysis The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues. Lipolyses
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014462 Ultrafiltration The separation of particles from a suspension by passage through a filter with very fine pores. In ultrafiltration the separation is accomplished by convective transport; in DIALYSIS separation relies instead upon differential diffusion. Ultrafiltration occurs naturally and is a laboratory procedure. Artificial ultrafiltration of the blood is referred to as HEMOFILTRATION or HEMODIAFILTRATION (if combined with HEMODIALYSIS).
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
August 1971, Rinsho byori. The Japanese journal of clinical pathology,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
October 1986, Indian journal of experimental biology,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
October 1967, Rivista critica di clinica medica,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
March 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
January 1964, Tijdschrift voor gastro-enterologie,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
January 1968, Journal of atherosclerosis research,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
January 1970, Problemy endokrinologii,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
January 1963, Journal of lipid research,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
July 1967, Nature,
S di Giulio, and B Lacour, and M Thevenin, and C Basile, and T Drüeke, and N K Man
November 1987, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Copied contents to your clipboard!